Inflammatory Bowel Diseases

Skip Navigation LinksHome > December 2013 - Volume 19 - Issue 13 > The Incidence and Predictors of Lupus-like Reaction in Patie...
Inflammatory Bowel Diseases:
doi: 10.1097/01.MIB.0000435435.91988.b6
Original Clinical Articles

The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies

Yanai, Henit MD*,†; Shuster, Dmitry MD; Calabrese, Emma MD, PhD§; Mlynarsky, Liat MD*,†; Tumuluri, Srilaxmi MD; Cohen, Russell D. MD

Collapse Box


Background: The incidence of lupus-like reactions (LLRs) in patients with inflammatory bowel disease (IBD) treated with anti-tumor necrosis factor (ATNF) has not been well defined. We aimed to characterize the features and predictors associated with LLR.

Methods: We studied a cohort of adult patients with IBD treated with ATNF by a single specialist during 2009. Patients with LLR were characterized and compared with those without LLR for possible predictors.

Results: Twenty of 289 patients (6.9%) had LLR (19.9 cases per 1000 patient-years). Female gender and IBD-unclassified were more prevalent in the LLR group (85% versus 54%, P = 0.009; and 15% versus 2.2%, P = 0.018, respectively), with a hazard ratio of 3.89 (95% confidence interval = 1.12–13.55; P = 0.033) and 7.38 (95% confidence interval = 1.93–28.23; P = 0.003), respectively. ATNF duration was shorter in the LLR group (median, 1 year [interquartile range, 0–3] versus 3 years [interquartile range, 1–6.5], P = 0.005). Arthropathy was universal, followed by fatigue and dermatitis (30% each). Antinuclear antibodies were universally positive, and 16 of 20 had anti–double-stranded DNA. ATNF was discontinued in all; 8 patients required corticosteroids and 1 required hydroxychloroquine followed by complete clinical resolution (mean 7.9 ± 5.9 months). Antinuclear antibodies reverted or normalized in 7 of 16 patients (44%). Fourteen patients (70%) were switched to a second ATNF, 2 with concomitant immunomodulators, and 12 as monotherapy. One patient on ATNF monotherapy developed a second LLR and was successfully switched to a third ATNF.

Conclusion: LLRs secondary to ATNFs are more frequent than previously reported, more common in women and IBD-unclassified. It is reversible with cessation of the culprit agent and steroids. Switching to an alternative ATNF rarely results in recurrence.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.